Subtype
Urothelial Neoplasm
CI-CAN-00001629Explore in graph →
Non-malignant236 active trials5 approved drugs8 evidence items
- NCIt
- C39852
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001629Explore in graph →
Clinical trials
625 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06818799 | Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer | completed | N/A | 50 | Helwan UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03523572 |
| Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer |
| completed |
| Phase 1 |
| 86 |
| Daiichi SankyoINDUSTRY |
| 7 |
| Jan 27, 2025 |
| clinicaltrials |
| NCT03240016 | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer(ABLE) | completed | Phase 2 | 36 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05522257 | PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas | completed | N/A | 25 | Leiden University Medical CenterOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03534804 | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma(PemCab) | completed | Phase 2 | 37 | University of UtahOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03658304 | Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | completed | Phase 2 | 29 | University of FloridaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02808143 | Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 9 | Northwestern UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06380062 | Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia | completed | — | 350 | Universität des SaarlandesOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05046665 | Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients(ZiPUP) | completed | Phase 1 | 11 | South Metropolitan Health ServiceOTHER_GOV | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT04200963 | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma | completed | Phase 1 | 78 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05700344 | SOGUG-AVELUMAB_RWD(SOGUG) | completed | — | 125 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03788746 | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma(PREVAIL) | completed | — | 181 | AstraZenecaINDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06193941 | Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits | completed | — | 400 | Zhongnan HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT04073602 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 19 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06169904 | B7-Family Score in Urothelial Carcinoma | completed | — | 215 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 14, 2023 | clinicaltrials |
| NCT04535921 | Fear of Cancer Recurrence in Genitourinary Cancer | completed | — | 500 | Ludwig-Maximilians - University of MunichOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03809013 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 64 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT02643043 | UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch | completed | N/A | 219 | Matthew Milowsky, MDOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT06020807 | Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer | completed | — | 168 | Nucleix Ltd.INDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT03636256 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 36 | NanOlogy, LLCINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05946369 | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | completed | — | 96 | Ain Shams UniversityOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03171493 | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy | completed | Phase 1 | 8 | Vyriad, Inc.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04314245 | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma | completed | — | 1,170 | AnchorDx Medical Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT03359239 | Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer | completed | Phase 1 | 10 | Matthew GalskyOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2025source: clinicaltrials